Reading NTLA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NTLA free→Reading NTLA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NTLA free→QuarterlyIQ Insights · NTLA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 13, 2026, the Company announced additional positive results from the global Phase 3 HAELO clinical trial of lonvoguran ziclumeran or “lonvo-z” (formerly NTLA-2002) for hereditary angioedema (“HAE”). The results were presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (“EAACI”) Annual Congress 2026 in Istanbul, Türkiye, and were simultaneously published in the New England Journal of Medicine . Intellia had previously rep…
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to
is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and will not be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference. Forward-Looking Statements This Current Report on Form 8-K an…
Entry into a Material Definitive Agreement. On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share. Pursuant to…
Other Events. Updates about Lonvo-z for the Treatment of HAE On April 27, 2026, Intellia announced positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z in HAE. Lonvo-z is an in vivo CRISPR gene editing candidate that is designed as a one-time treatment, administered in an outpatient setting, to inactivate the kallikrein B1 (“ KLKB1 ”) gene to permanently lower kallikrein and bradykinin levels. HAELO is a randomized, double-blind, placebo-controlled Phase 3 trial de…
Other Events. On March 2, 2026, Intellia announced that the U.S. Food and Drug Administration (“FDA”) has removed the clinical hold on the investigational new drug application (“IND”) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (“nex-z”) for patients with transthyretin (“ATTR”) amyloidosis with cardiomyopathy (“ATTR-CM”). On October 29, 2025, the FDA imposed a clinical hold on the INDs for the MAGNITUDE Phase 3 trial and the MAGNITUDE-2 Phase 3 clinical trial of nex-z for…
Entry into a Material Definitive Agreement. Intellia Therapeutics, Inc. (the “Company”) previously entered into an Open Market Sale Agreement, dated March 4, 2022, and amended on February 23, 2024 (as amended, the “Sales Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggrega…
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to
Other Events. On January 27, 2026, Intellia announced that the U.S. Food and Drug Administration (“FDA”) has removed the clinical hold on the investigational new drug application (“IND”) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (“nex-z”) for patients with hereditary transthyretin (“ATTR”) amyloidosis with polyneuropathy (“ATTRv-PN”). On October 29, 2025, the FDA imposed a clinical hold on the INDs for the MAGNITUDE-2 trial and the MAGNITUDE Phase 3 clinical trial of…
Other Events. As the Company reported on October 27, 2025, Grade 4 liver transaminases and increased total bilirubin were reported in a patient who was dosed with nexiguran ziclumeran (“nex-z”) in the MAGNITUDE trial of nex-z for the treatment of transthyretin (“ATTR”) amyloidosis with cardiomyopathy (“ATTR-CM”). This case met the trial’s protocol-defined pausing criteria, and the United States Food and Drug Administration (the “FDA”) subsequently placed a clinical hold on the Investigational…
Other Events. Phase 1/2 Data for Lonvoguran Ziclumeran On November 8, 2025, the Company announced positive new clinical data from the ongoing Phase 1/2 trial of lonvoguran ziclumeran (“lonvo-z,” also known as NTLA-2002) in patients with hereditary angioedema (“HAE”). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy that is currently in development as a one-time treatment for HAE. The global Phase 1/2 trial is evaluating the safety and efficacy of lonvo-z in adults with…
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to
Other Events. On October 29, 2025, the United States Food and Drug Administration (the “FDA”) verbally informed the Company that the FDA has placed a clinical hold on the Investigational New Drug applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran (“nex-z”). FDA indicated that it would provide a formal Clinical Hold Letter within 30 calendar days. The clinical hold follows the previously disclosed report of Grade 4 liver transaminases and increased…
Other Events. On September 25, 2025, the Company announced positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (“nex-z,” also known as NTLA-2001) in patients with hereditary transthyretin (“ATTR”) amyloidosis with polyneuropathy (“ATTRv-PN”). Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. The Phase 1 trial is an open-label study evaluating the safety and activity of nex-z in patie…
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 7, 2025, the Company announced that Dr. David Lebwohl, M.D., the Company’s Executive Vice President and Chief Medical Officer (“CMO”), will retire from the Company, effective August 7, 2026. Upon his retirement, Dr. Lebwohl will be eligible for the equity treatment set forth in the Company’s Amended and Restated Retirement Policy for Equi…
Other Events. On June 15, 2025, the Company announced positive new clinical data from the ongoing Phase 1/2 trial of lonvoguran ziclumeran (“lonvo-z,” also known as NTLA-2002) in patients with hereditary angioedema (“HAE”). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for HAE. The Phase 1/2 trial is an open-label, two-part study evaluating the safety and activity of lonvo-z in patients with HAE. In the Phase 1 portion of the st…
Other Events. On May 18, 2025, the Company announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z, also known as NTLA-2001) in patients with transthyretin (ATTR) amyloidosis. Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. The Phase 1 trial is an open-label, two-part study evaluating the safety and activity of nex-z in patients with either ATTR a…
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to
of this Current Report on Form 8-K. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: February 21, 2025 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President
Entry into a Material Definitive Agreement. On February 18, 2025, Intellia Therapeutics, Inc. (the “Company”) entered into a Lease Agreement (the “Tech Square Lease”) with ARE-Tech Square, LLC, an affiliate of Alexandria Real Estate Equities, Inc. (the “Tech Square Landlord”) for office and laboratory space located at 400 Technology Square, Cambridge, Massachusetts (“400 Tech Square”). Under the terms of the Tech Square Lease, the Company will initially lease approximately 101,000 square feet…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.